- Home
- JANX vs JBGS Comparison
JANX vs JBGS Comparison
Compare JANX & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | JBGS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 975.7M | 823.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | JANX | JBGS |
|---|---|---|
| Price | $16.62 | $11.26 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 13 | 1 |
| Target Price | ★ $47.00 | $15.00 |
| AVG Volume (30 Days) | ★ 853.7K | 741.0K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,000,000.00 | ★ $498,598,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.12 | $10.77 |
| 52 Week High | $35.34 | $23.85 |
Technical Indicators
Market Signals| Indicator | JANX | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 36.53 |
| Support Level | $13.09 | $10.91 |
| Resistance Level | $16.68 | $16.00 |
| Average True Range (ATR) | 0.80 | 0.30 |
| MACD | -0.40 | 0.02 |
| Stochastic Oscillator | 10.77 | 15.35 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.